The United States Patent and Trademark Office (USPTO) has granted the company’s patent application directed to gluconic acid derivatives for preventing and/or treating bacterial infections.

“The US patent covering treatment and prevention of vaginal bacterial infections by GDL, or pHyph, strengthens Gedea’s position in one of the largest markets for treatment of these conditions. pHyph has the potential to replace a substantial share of the antimicrobials used for vaginal infections today,” says Annette Säfholm, Gedea Biotech’s CEO.

The patent can be kept in force until 2038. The specific derivative Glucone-delta lactone (GDL) in pHyph is a well-documented substance with a low risk of developing antimicrobial resistance.

Gedea Biotech additionally holds granted patents within the same patent family in Singapore and Ukraine, as well as granted patents for treatment of fungal infections in USA, Japan, Europe, China, South Korea, Australia, Mexico, Ukraine, Israel, Chile, Hong Kong, South Africa and Singapore, and is in IPT-phase for a patent on formulation of the tablet.

Photo of Annette Säfholm: Gedea Biotech